Paul B. Robbins

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer, Konstantin Penkov, John B.A.G. Haanen et al. · New England Journal of Medicine · 2019 · 2.5K citations · Full text

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

Robert J. Motzer, Paul B. Robbins, Thomas Powles et al. · Nature Medicine · 2020 · 503 citations · Full text

Urology, Axitinib Versus Sunitinib, Genitourinary Cancer +8

Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial

Toni K. Choueiri, James Larkin, Mototsugu Oya et al. · The Lancet Oncology · 2018 · 257 citations

Phase 1B, Urology, Oncology +7

Use of human tissue to assess the oncogenic activity of melanoma-associated mutations

Yakov Chudnovsky, Amy E. Adams, Paul B. Robbins et al. · Nature Genetics · 2005 · 198 citations · Full text

Somatic Variant, Oncogenic Agent, Medicine +11

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma

Marlon C. Rebelatto, Anita Midha, Amita Mistry et al. · Diagnostic Pathology · 2016 · 177 citations · Full text